Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 16, 2017. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not contain corporate financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports on specific share transactions.
| Instrument | Transaction Date | Price | Total Volume |
|---|---|---|---|
| Ordinary Shares (GBP) | 2017-10-12 | £15.2750 | 34,078.887 |
| American Depositary Shares (USD) | 2017-10-12 | $41.02 | 5,778.646 |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details an increase in notional interest in shares for eleven executives following the re-investment of dividends paid on October 12, 2017, under the Company's 2009 Performance Share Plan.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, future guidance, outlook, risks, contingencies, or unusual items. It is a regulatory disclosure of specific share plan transactions.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were automatic re-investments of dividends, not open market purchases or sales.
- Participants: Transactions involved 11 senior executives, including the CEO (Ms E Walmsley), CFO (Mr S Dingemans), and President of R&D (Dr P J T Vallance).
- Share Plan: All activity relates to the 2009 Performance Share Plan.
- Valuation: The filing confirms the share price used for re-investment was £15.2750 for Ordinary Shares and $41.02 for ADSs on October 12, 2017.
- Financial Data: Investors should look to other filings (e.g., Form 20-F or quarterly reports) for revenue, earnings, and cash flow data, as this document contains none.